Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30431
Title: | Variations in whole brain radiation therapy fractionation for brain metastases in Victoria. | Austin Authors: | Chee, Lessandra Yan Shan;Sia, Joseph;Milne, Roger L;Foroudi, Farshad ;Millar, Jeremy L;Ong, Wee Loon | Affiliation: | Olivia Newton-John Cancer Wellness and Research Centre School of Clinical Medicine, University of Cambridge, Cambridge, UK.. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.. Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.. Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia.. Alfred Health Radiation Oncology, Melbourne, Victoria, Australia.. Central Clinical School, Monash University, Melbourne, Victoria, Australia.. Radiation Oncology |
Issue Date: | 21-Jun-2022 | Date: | 2022 | Publication information: | Journal of Medical Imaging and Radiation Oncology 2022; 66(8) | Abstract: | We aim to evaluate the use of different whole brain radiation therapy (WBRT) fractionation schedules for brain metastases (BM) in Victoria, and the factors associated with it. This is a population-based cohort of patients who received radiation therapy for BM between 2012 and 2017, as captured in the Victorian Radiotherapy Minimum Dataset. We excluded patients with primary brain tumour and those who had 'prophylactic' intent treatment. The Cochran-Armitage test was used to evaluate changing trend in WBRT fractionation. Multivariate multinomial logistic regressions were used to evaluate factors associated with WBRT fractionation. Of the 3111 patients who had WBRT, 1048 (45%), 1291 (42%) and 312 (13%) had ≤5, 6-10 and >10 fractions WBRT respectively. There was progressive increase in ≤5 fractions WBRT use over time, from 37% in 2012 to 50% in 2017 (P-trend < 0.001). In multivariate analyses, increasing age, patients with gastrointestinal cancer, patients living in remote/regional areas and more recent treatment were associated with the use of shorter WBRT fractionation (≤5 fractions), while patients who had WBRT plus stereotactic radiosurgery, and those treated in private institutions were associated with the use of prolonged WBRT fractionation (≥6 fractions). Three hundred eighty-nine (13%) patients died within 30 days of WBRT, of which 241 (64%), 119 (32%) and 17 (5%) had ≤5, 6-10 and > 10 fractions WBRT respectively. We observed large variations in WBRT fractionation that are associated with patient, tumour, treatment and institutional factors. It is important to continuously monitor and benchmark our practice in order to reduce potentially unwarranted variations. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30431 | DOI: | 10.1111/1754-9485.13447 | ORCID: | https://orcid.org/0000-0002-9056-0903 https://orcid.org/0000-0001-8387-0965 https://orcid.org/0000-0001-8202-8602 https://orcid.org/0000-0001-6657-7193 |
Journal: | Journal of medical imaging and radiation oncology | PubMed URL: | 35726760 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35726760/ | Type: | Journal Article | Subjects: | brain metastases whole brain radiation therapy |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.